Peptides Science: 2026 Multi-Omics Data Reveals 40% Growth in Therapeutic Peptide Pipeline
Abstract: 2026 multi-omics data reveals a 40% expansion in the therapeutic peptide pipeline, driven by advances in proteomics and AI-driven design. Product composition now integrates cyclic, stapled, and cell-penetrating peptides, enhancing stability and bioavailability. Industry outlook remains robust, with oncology and metabolic disorders leading indications. Comparative analysis shows improved target specificity over small molecules and reduced immunogenicity versus biologics. Selection guidelines prioritize bioavailability, half-life, and manufacturing scalability. Key industry knowledge includes regulatory shifts toward peptide-based precision therapies and multi-omics integration for accelerated discovery.